Global Healthcare

European Obesity Market on Track to Show Drug, Device Gains

1 Mins read

The FDA put a slight dent in forecasts for obesity drugs, with a negative view (and decisions) in 2010 that it now seems to be backing away from.

Having forecasted the obesity market earlier this year and having taken a position that the FDA might well revisit its negative decisions on Contrave, Lorcaserin and Qnexa (especially if additional trial data is submitted to address specific concerns), we still hold that there will be substantial upside in obesity drugs (and devices) over the coming decade.

The FDA put a slight dent in forecasts for obesity drugs, with a negative view (and decisions) in 2010 that it now seems to be backing away from.

Having forecasted the obesity market earlier this year and having taken a position that the FDA might well revisit its negative decisions on Contrave, Lorcaserin and Qnexa (especially if additional trial data is submitted to address specific concerns), we still hold that there will be substantial upside in obesity drugs (and devices) over the coming decade.

This is especially true for Europe which, at least in principle, is unaffected by FDA decisions. Below is our forecast of the obesity products market, by specific drug and device types, for Europe through 2019 (sales in $millions). 

 

Eurobesity

 

Source: MedMarket Diligence, LLC; Report S835.

 

Posted via email from medmarket’s posterous

     

Avatar
183 posts

About author
I serve the interests of medical technology company decision-makers, venture-capitalists, and others with interests in medtech producing worldwide analyses of medical technology markets for my audience of mostly medical technology companies (but also rapidly growing audience of biotech, VC, and other healthcare decision-makers). I have a small staff and go to my industry insiders (or find new ones as needed) to produce detailed, reality-grounded analyses of current and potential markets and opportunities. I am principally interested in those core clinical applications served by medical devices, which are expanding to include biomaterials, drug-device hybrids and other non-device technologies either competing head-on with devices or being integrated with devices in product development. The effort and pain of making every analysis global in scope is rewarded by my audience's loyalty, since in the vast majority of cases they too have global scope in their businesses. Specialties: Business analysis through syndicated reports, and select custom engagements, on medical technology applications and markets in general/abdominal/thoracic surgery, interventional cardiology, cardiothoracic surgery, patient monitoring/management, wound management, cell therapy, tissue engineering, gene therapy, nanotechnology, and others.
Articles
Related posts
Global HealthcarePolicy & Law

5 Tactics for Safeguarding the Global Health Industry Post-Covid-19

2 Mins read
We are beginning to enter into a new era in the fight against Covid-19, but there is yet more work to be…
Global Healthcare

How Physical Therapy Can Done Virtually

2 Mins read
As technology continues to advance, an increasing number of patients are turning to telehealth for their healthcare needs. While many facets of…
Global Healthcare

Considering An Insulin Pump? Here's What You Need To Know

3 Mins read
Whether you have Type 1 or Type 2 diabetes, your body needs additional insulin. If you have Type 1 diabetes, you may…